Real world effectiveness of warfarin among ischemic stroke patients with atrial fibrillation

Observational analysis from Patient-Centered Research into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) study

Ying Xian, Jingjing Wu, Emily C. O'Brien, Gregg C. Fonarow, Daiwai M. Olson, Lee H. Schwamm, Deepak L. Bhatt, Eric E. Smith, Robert E Suter, Deidre Hannah, Brianna Lindholm, Lesley Maisch, Melissa A. Greiner, Barbara L. Lytle, Michael J. Pencina, Eric D. Peterson, Adrian F. Hernandez

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

OBJECTIVE: To examine the association between warfarin treatment and longitudinal outcomes after ischemic stroke in patients with atrial fibrillation in community practice. DESIGN: Observational study. SETTING: Hospitals (n=1487) participating in the Get With The Guidelines (GWTG)-Stroke program in the United States, from 2009 to 2011. PARTICIPANTS: 12 552 warfarin naive atrial fibrillation patients admitted to hospital for ischemic stroke and treated with warfarin compared with no oral anticoagulant at discharge, linked to Medicare claims for longitudinal outcomes. MAIN OUTCOME MEASURES: Major adverse cardiovascular events (MACE) and home time, a patient centered outcomes measure defined as the total number of days free from institutional care after discharge. A propensity score inverse probability weighting method was used to account for all differences in observed characteristics between treatment groups. RESULTS: Among 12 552 survivors of stroke, 11 039 (88%) were treated with warfarin at discharge. Warfarin treated patients were slightly younger and less likely to have a history of previous stroke or coronary artery disease but had similar severity of stroke as measured by the National Institutes of Health Stroke Scale. Relative to those not treated, patients treated with warfarin had more days at home (as opposed to institutional care) during the two years after discharge (adjusted home time difference 47.6 days, 99% confidence interval 26.9 to 68.2). Patients discharged on warfarin treatment also had a reduced risk of MACE (adjusted hazard ratio 0.87, 99% confidence interval 0.78 to 0.98), all cause mortality (0.72, 0.63 to 0.84), and recurrent ischemic stroke (0.63, 0.48 to 0.83). These differences were consistent among clinically relevant subgroups by age, sex, stroke severity, and history of previous coronary artery disease and stroke. CONCLUSIONS: Among ischemic stroke patients with atrial fibrillation, warfarin treatment was associated with improved long term clinical outcomes and more days at home. CLINICAL TRIAL REGISTRATION: Clinical trials NCT02146274.

Original languageEnglish (US)
Article numberh3786
JournalBMJ (Online)
Volume351
DOIs
StatePublished - Jul 31 2015
Externally publishedYes

Fingerprint

Patient Outcome Assessment
Warfarin
Atrial Fibrillation
Stroke
Research
Coronary Artery Disease
Clinical Trials
Confidence Intervals
Propensity Score
National Institutes of Health (U.S.)
Medicare
Anticoagulants
Observational Studies
Survivors

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Real world effectiveness of warfarin among ischemic stroke patients with atrial fibrillation : Observational analysis from Patient-Centered Research into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) study. / Xian, Ying; Wu, Jingjing; O'Brien, Emily C.; Fonarow, Gregg C.; Olson, Daiwai M.; Schwamm, Lee H.; Bhatt, Deepak L.; Smith, Eric E.; Suter, Robert E; Hannah, Deidre; Lindholm, Brianna; Maisch, Lesley; Greiner, Melissa A.; Lytle, Barbara L.; Pencina, Michael J.; Peterson, Eric D.; Hernandez, Adrian F.

In: BMJ (Online), Vol. 351, h3786, 31.07.2015.

Research output: Contribution to journalArticle

Xian, Y, Wu, J, O'Brien, EC, Fonarow, GC, Olson, DM, Schwamm, LH, Bhatt, DL, Smith, EE, Suter, RE, Hannah, D, Lindholm, B, Maisch, L, Greiner, MA, Lytle, BL, Pencina, MJ, Peterson, ED & Hernandez, AF 2015, 'Real world effectiveness of warfarin among ischemic stroke patients with atrial fibrillation: Observational analysis from Patient-Centered Research into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) study', BMJ (Online), vol. 351, h3786. https://doi.org/10.1136/bmj.h3786
Xian, Ying ; Wu, Jingjing ; O'Brien, Emily C. ; Fonarow, Gregg C. ; Olson, Daiwai M. ; Schwamm, Lee H. ; Bhatt, Deepak L. ; Smith, Eric E. ; Suter, Robert E ; Hannah, Deidre ; Lindholm, Brianna ; Maisch, Lesley ; Greiner, Melissa A. ; Lytle, Barbara L. ; Pencina, Michael J. ; Peterson, Eric D. ; Hernandez, Adrian F. / Real world effectiveness of warfarin among ischemic stroke patients with atrial fibrillation : Observational analysis from Patient-Centered Research into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) study. In: BMJ (Online). 2015 ; Vol. 351.
@article{5ca43c7ee255447a86ef09fd6e953141,
title = "Real world effectiveness of warfarin among ischemic stroke patients with atrial fibrillation: Observational analysis from Patient-Centered Research into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) study",
abstract = "OBJECTIVE: To examine the association between warfarin treatment and longitudinal outcomes after ischemic stroke in patients with atrial fibrillation in community practice. DESIGN: Observational study. SETTING: Hospitals (n=1487) participating in the Get With The Guidelines (GWTG)-Stroke program in the United States, from 2009 to 2011. PARTICIPANTS: 12 552 warfarin naive atrial fibrillation patients admitted to hospital for ischemic stroke and treated with warfarin compared with no oral anticoagulant at discharge, linked to Medicare claims for longitudinal outcomes. MAIN OUTCOME MEASURES: Major adverse cardiovascular events (MACE) and home time, a patient centered outcomes measure defined as the total number of days free from institutional care after discharge. A propensity score inverse probability weighting method was used to account for all differences in observed characteristics between treatment groups. RESULTS: Among 12 552 survivors of stroke, 11 039 (88{\%}) were treated with warfarin at discharge. Warfarin treated patients were slightly younger and less likely to have a history of previous stroke or coronary artery disease but had similar severity of stroke as measured by the National Institutes of Health Stroke Scale. Relative to those not treated, patients treated with warfarin had more days at home (as opposed to institutional care) during the two years after discharge (adjusted home time difference 47.6 days, 99{\%} confidence interval 26.9 to 68.2). Patients discharged on warfarin treatment also had a reduced risk of MACE (adjusted hazard ratio 0.87, 99{\%} confidence interval 0.78 to 0.98), all cause mortality (0.72, 0.63 to 0.84), and recurrent ischemic stroke (0.63, 0.48 to 0.83). These differences were consistent among clinically relevant subgroups by age, sex, stroke severity, and history of previous coronary artery disease and stroke. CONCLUSIONS: Among ischemic stroke patients with atrial fibrillation, warfarin treatment was associated with improved long term clinical outcomes and more days at home. CLINICAL TRIAL REGISTRATION: Clinical trials NCT02146274.",
author = "Ying Xian and Jingjing Wu and O'Brien, {Emily C.} and Fonarow, {Gregg C.} and Olson, {Daiwai M.} and Schwamm, {Lee H.} and Bhatt, {Deepak L.} and Smith, {Eric E.} and Suter, {Robert E} and Deidre Hannah and Brianna Lindholm and Lesley Maisch and Greiner, {Melissa A.} and Lytle, {Barbara L.} and Pencina, {Michael J.} and Peterson, {Eric D.} and Hernandez, {Adrian F.}",
year = "2015",
month = "7",
day = "31",
doi = "10.1136/bmj.h3786",
language = "English (US)",
volume = "351",
journal = "BMJ (Online)",
issn = "0959-8146",
publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - Real world effectiveness of warfarin among ischemic stroke patients with atrial fibrillation

T2 - Observational analysis from Patient-Centered Research into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) study

AU - Xian, Ying

AU - Wu, Jingjing

AU - O'Brien, Emily C.

AU - Fonarow, Gregg C.

AU - Olson, Daiwai M.

AU - Schwamm, Lee H.

AU - Bhatt, Deepak L.

AU - Smith, Eric E.

AU - Suter, Robert E

AU - Hannah, Deidre

AU - Lindholm, Brianna

AU - Maisch, Lesley

AU - Greiner, Melissa A.

AU - Lytle, Barbara L.

AU - Pencina, Michael J.

AU - Peterson, Eric D.

AU - Hernandez, Adrian F.

PY - 2015/7/31

Y1 - 2015/7/31

N2 - OBJECTIVE: To examine the association between warfarin treatment and longitudinal outcomes after ischemic stroke in patients with atrial fibrillation in community practice. DESIGN: Observational study. SETTING: Hospitals (n=1487) participating in the Get With The Guidelines (GWTG)-Stroke program in the United States, from 2009 to 2011. PARTICIPANTS: 12 552 warfarin naive atrial fibrillation patients admitted to hospital for ischemic stroke and treated with warfarin compared with no oral anticoagulant at discharge, linked to Medicare claims for longitudinal outcomes. MAIN OUTCOME MEASURES: Major adverse cardiovascular events (MACE) and home time, a patient centered outcomes measure defined as the total number of days free from institutional care after discharge. A propensity score inverse probability weighting method was used to account for all differences in observed characteristics between treatment groups. RESULTS: Among 12 552 survivors of stroke, 11 039 (88%) were treated with warfarin at discharge. Warfarin treated patients were slightly younger and less likely to have a history of previous stroke or coronary artery disease but had similar severity of stroke as measured by the National Institutes of Health Stroke Scale. Relative to those not treated, patients treated with warfarin had more days at home (as opposed to institutional care) during the two years after discharge (adjusted home time difference 47.6 days, 99% confidence interval 26.9 to 68.2). Patients discharged on warfarin treatment also had a reduced risk of MACE (adjusted hazard ratio 0.87, 99% confidence interval 0.78 to 0.98), all cause mortality (0.72, 0.63 to 0.84), and recurrent ischemic stroke (0.63, 0.48 to 0.83). These differences were consistent among clinically relevant subgroups by age, sex, stroke severity, and history of previous coronary artery disease and stroke. CONCLUSIONS: Among ischemic stroke patients with atrial fibrillation, warfarin treatment was associated with improved long term clinical outcomes and more days at home. CLINICAL TRIAL REGISTRATION: Clinical trials NCT02146274.

AB - OBJECTIVE: To examine the association between warfarin treatment and longitudinal outcomes after ischemic stroke in patients with atrial fibrillation in community practice. DESIGN: Observational study. SETTING: Hospitals (n=1487) participating in the Get With The Guidelines (GWTG)-Stroke program in the United States, from 2009 to 2011. PARTICIPANTS: 12 552 warfarin naive atrial fibrillation patients admitted to hospital for ischemic stroke and treated with warfarin compared with no oral anticoagulant at discharge, linked to Medicare claims for longitudinal outcomes. MAIN OUTCOME MEASURES: Major adverse cardiovascular events (MACE) and home time, a patient centered outcomes measure defined as the total number of days free from institutional care after discharge. A propensity score inverse probability weighting method was used to account for all differences in observed characteristics between treatment groups. RESULTS: Among 12 552 survivors of stroke, 11 039 (88%) were treated with warfarin at discharge. Warfarin treated patients were slightly younger and less likely to have a history of previous stroke or coronary artery disease but had similar severity of stroke as measured by the National Institutes of Health Stroke Scale. Relative to those not treated, patients treated with warfarin had more days at home (as opposed to institutional care) during the two years after discharge (adjusted home time difference 47.6 days, 99% confidence interval 26.9 to 68.2). Patients discharged on warfarin treatment also had a reduced risk of MACE (adjusted hazard ratio 0.87, 99% confidence interval 0.78 to 0.98), all cause mortality (0.72, 0.63 to 0.84), and recurrent ischemic stroke (0.63, 0.48 to 0.83). These differences were consistent among clinically relevant subgroups by age, sex, stroke severity, and history of previous coronary artery disease and stroke. CONCLUSIONS: Among ischemic stroke patients with atrial fibrillation, warfarin treatment was associated with improved long term clinical outcomes and more days at home. CLINICAL TRIAL REGISTRATION: Clinical trials NCT02146274.

UR - http://www.scopus.com/inward/record.url?scp=84942311361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942311361&partnerID=8YFLogxK

U2 - 10.1136/bmj.h3786

DO - 10.1136/bmj.h3786

M3 - Article

VL - 351

JO - BMJ (Online)

JF - BMJ (Online)

SN - 0959-8146

M1 - h3786

ER -